The clinical utility of fibrin-related biomarkers in sepsis

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 8, 2013, Pages 839-843

  Toh, Julien M H ^a   Ken Dror, Gie ^b   Downey, Colin ^d   Abrams, Simon T ^c,d  

^a UK   (United Kingdom)

^b Departments of Biostatistics   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

D dimer; fibrin; fibrin degradation products; outcome; sepsis

Indexed keywords

ANTITHROMBIN III; D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRIN MONOMER; FIBRINOGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; IN VIVO STUDY; INTENSIVE CARE UNIT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MORTALITY; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROTHROMBIN TIME; SEPSIS; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE COUNT;

AGED; ANTITHROMBIN III; BIOLOGICAL MARKERS; BLOOD PLATELETS; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROTHROMBIN TIME; SEPSIS; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84888138753     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283646659     Document Type: Article

References (23)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310.
2. Reinhart K, Kissoon NT, Daniels R, Jimenez EJ. Stop sepsis-save lives: a call to join the global coalition for the World Sepsis Day. J Crit Care 2012; 27:410-413.
3. Watson R. Multidrug resistance responsible for half of deaths from healthcare associated infections in Europe. BMJ 2008; 336:1266-1267.
4. Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res 2003; 60:26-39.
5. Soshitova NP, Karamzin SS, Balandina AN, Fadeeva OA, Kretchetova AV, Galstian GM, et al. Predicting prothrombotic tendencies in sepsis using spatial clot growth dynamics. Blood Coagul Fibrinolysis 2012; 23:498-507.
6. Dutt T, Toh CH. The Yin-Yang of thrombin and activated protein C. Br J Haematol 2008; 140:505-515.
7. Gaffney PJ. Fibrin degradation products. A review of structures found in vitro and in vivo. Ann N Y Acad Sci 2001; 936:594-610.
8. Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thromb Vasc Biol 2011; 31:494-499.
9. Ieko M, Nakabayashi T, Tarumi T, Naito S, Yoshida M, Kanazawa K, et al. Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis. Clin Chim Acta 2007; 386:38-45.
10. Dempfle CE, Wurst M, Smolinski M, Lorenz S, Osika A, Olenik D, et al. Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score. Thromb Haemost 2004; 91:812-818.
11. Dempfle CE, Zips S, Ergul H, Heene DL. The fibrin assay comparison trial (FACT): correlation of soluble fibrin assays with D-dimer. Thromb Haemost 2001; 86:1204-1209.
12. Surviving Sepsis Campaign: International guidelines. 2008; Available from: http://www. survivingsepsis. org/SiteCollectionDocuments/Final 08 SSC Guidelines. pdf.
13. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655.
14. Green D. Coagulation cascade. Hemodial Int 2006; 10 (Suppl 2):S2-S4.
15. Wiedermann CJ. Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis. Crit Care 2006; 10:209.
16. Edbrooke DL, Hibbert CL, Kingsley JM, Smith S, Bright NM, Quinn JM. The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 1999; 27:1760-1767.
17. Blanco J, Muriel-Bombin A, Sagredo V, Taboada F, Gandia F, Tamayo L, et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit Care 2008; 12:R158.
18. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873.
19. Stief TW, Ijagha O, Weiste B, Herzum I, Renz H, Max M. Analysis of hemostasis alterations in sepsis. Blood Coagul Fibrinolysis 2007; 18:179-186.
20. Rahr HB, Sorensen JV, Danielsen D. Markers of coagulation and fibrinolysis in blood drawn into citrate with and without D-Phe-Pro-Arg- Chloromethylketone (PPACK). Thromb Res 1994; 73:279-284.
21. Palareti G, Legnani C, Cosmi B, Valdre L, Lunghi B, Bernardi F, Coccheri S. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108:313-318.
22. Skansberg P, Cronberg S, Nilsson IM. The occurrence and significance of fibrin-fibrinogen degradation products (FDP) in acute infections. Scand J Infect Dis 1974; 6:197-203.
23. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003; 31:1737-1741.